Lefamulin最初由Nabriva开发,2018年3月仑胜医药获得在大中华区,包括中国大陆、香港、澳门、台湾开...查看全文
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-028847 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-028848 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-028849 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-028850 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-028851 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-028852 Size: 4 KB 网页链接
$Nabriva Therapeutics(NBRV)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0001193125-20-033287 Act: 34 Size: 79 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 8-K Current report, item 5.02 Accession Number: 0001104659-20-019213 Act: 34 Size: 24 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-015176 Size: 7 KB 网页链接
$Nabriva Therapeutics(NBRV)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001104659-20-015178 Size: 7 KB 网页链接